CD4+ CAR T-cell expansion is associated with response and …
网页2023年6月17日 · It has been shown that the different composition of CD4+ and CD8+ CAR T-cell populations as well as effector and memory cells influences the efficacy of CAR T-cell therapy [6, 7]. In...
Optimizing the manufacturing and antitumour response of CAR T …
网页2023年2月14日 · Phenotypes of chimeric antigen receptor T (CAR T) cell products, including CD4:CD8 ratio, memory composition and specific CD4 + T cell subsets, affect clinical efficacy after adoptive...
CD4 + CAR T cells — more than helpers - Nature
网页2023年5月29日 · Therapeutic products containing CD8 + and CD4 + T cells expressing CARs are effective at inducing remission in patients with cancer. How CD4 + CAR T cells contribute to the anti-tumor...
The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor …
网页CD4 + and CD8 + chimeric antigen receptor T cells (CAR-T) play different roles in the in vivo anti-tumour response, but the role of the CD4 + /CD8 + ratio among infused CAR-T has not been clearly defined yet. We analysed leftovers from infused anti-CD19 CAR-T bags of 31 patients with aggressive B-cell lymphomas.
Key role of CD4+ T cells in determining CD8 function during CAR-T …
网页2024年3月13日 · In other words, the ligation on CD8+CAR T cells with CD4+CAR T cells by CD4-CD40L or CD27-CD70 (respectively) provides a costimulatory signal that, paired with cytokines produced by CD4+T cells, increases ex vivo expansion and contributes to a more functional phenotype. This corroborates with data from a …
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T ...
网页2016年3月15日 · This review is focused on different subsets of T cells: CD4 and CD8, memory and effector functions, and their role in CAR-T therapy--a cellular adoptive immunotherapy with T cells expressing chimeric antigen receptor. The CAR-T cells recognize tumor antigens and induce cytotoxic activities against tumor cells.
Advancement and Challenges in Monitoring of CAR-T Cell …
网页1 天前 · The essential information is comparing the proportion between CD4+ and CD8+ CAR-T cells. When contrasting the utilization of separate T-cell subsets for CAR-T cells, the concurrent application of CD4+ and CD8+ subsets demonstrates synergistic anti-cancer properties . A recent study tracking the progress of two patients a decade after CAR-T cell ...
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B ... - PubMed
网页2016年6月1日 · CD8+ T cell-mediated anti-CAR transgene product immune responses developed after CAR-T cell infusion in some patients, limited CAR-T cell persistence, and increased relapse risk. Addition of fludarabine to the lymphodepletion regimen improved CAR-T cell persistence and disease-free survival.
CD4 CAR-T cells targeting CD19 play a key role in exacerbating …
网页Recent clinical data support the key role of CD4 chimeric antigen receptors (CAR)-T cells targeting CD19 in maintaining long-term antitumor responses. However, the relative contribution of CD4 and CD8 CAR-T cell subsets to cytokine release syndrome (CRS) development has not been thoroughly investigated yet.
Improved Expansion and Function of CAR T Cell Products from …
网页2018年11月29日 · Preclinical data demonstrate superior in vivo anti-tumor efficacy of cell products consisting of equal numbers of CD4 + and CD8 + T cells, and a recent clinical trial, in which CD19-targeted CAR T cell products were infused at a 1:1 ratio of CD4:CD8 T cells, showed clear dose-response and dose-toxicity relationships.